Phase I/II Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Single, Hourly-Repeating, Escalating Doses of PER977 Following a Single Subcutaneous Dose of Enoxaparin

Trial Profile

Phase I/II Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Single, Hourly-Repeating, Escalating Doses of PER977 Following a Single Subcutaneous Dose of Enoxaparin

Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 Oct 2016

At a glance

  • Drugs Ciraparantag (Primary)
  • Indications Haemorrhage
  • Focus Adverse reactions
  • Sponsors Perosphere
  • Most Recent Events

    • 29 Oct 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 05 Aug 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top